Alembic Pharmaceuticals has received the US health regulator’s nod for a drug used to treat overactive bladder with symptoms of urinary incontinence, urgency and frequency.
“The company has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darifenacin extended release tablets, 7.5mg and 15mg,” Alembic Pharmaceuticals said in a BSE filing today.
The approved product is equivalent to Enablex of Allergan Pharmaceuticals. According to IMS December 2016 data, Darifenacin extended release tablets had an estimated market size of $64 million. The company now has a total of 70 ANDA approvals from the USFDA. The stock was trading at Rs 529, up 2.16 per cent, on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.